Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.48 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242522 | 0.87 | MMP2 (0.48) | F2RL1ALDH1A1 | |
| SCHEMBL2249532 | 0.85 | CHRM2 (0.49) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL2242399 | 0.85 | KMT2A (0.56) | SMN1; SMN2KMT2APLAAT3PLAAT5PLAAT2 | |
| SCHEMBL2248284 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTKMT2AF2RL1PLAAT3 | |
| SCHEMBL3449139 | 0.84 | GGT1 (0.55) | KMT2APLAAT5PLAAT4MEN1 | |
| SCHEMBL2246539 | 0.84 | GGT1 (0.55) | KMT2APLAAT5PLAAT4MEN1 | |
| SCHEMBL9487676 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTKMT2A | |
| SCHEMBL2248685 | 0.83 | FOLH1 (0.44) | KMT2APLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL2244468 | 0.83 | HSD17B10 (0.47) | KMT2APLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL2244986 | 0.83 | FOLH1 (0.44) | KMT2APLAAT3PLAAT5PLAAT2PLAAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998965-B2 | Glutamate aggrecanase inhibitors | WYETH LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2010-01-14 | — | — | US | disclosed |
| US-7553873-B2 | Glutamate aggrecanase inhibitors | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1902014-A2 | GLUTAMATE AGGRECANASE INHIBITORS | Wyeth (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | WYETH (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007008994-A2 | GLUTAMATE AGGRECANASE INHIBITORS | WYETH (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010012-A1 | GLUTAMATE AGGRECANASE INHIBITORS | ADAMTS5, ADAMTS1, ADAMTS7 | SMN1; SMN2 2624/4885HTT 762/4885KMT2A 2364/4885 |
| US-20070043066-A1 | Glutamate aggrecanase inhibitors | ADAMTS5, ADAMTS1, ADAMTS7 | SMN1; SMN2 2624/4885HTT 762/4885KMT2A 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.